Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Tonix Pharma ( (TNXP) ) has issued an announcement.
On March 10, 2025, Tonix Pharmaceuticals announced receiving a $50,000 grant from the Medical CBRN Defense Consortium to support the development of its TNX-801 vaccine candidate for mpox and smallpox. The grant will aid in creating a commercialization plan for TNX-801, which has shown promising results, including being significantly less virulent than traditional smallpox vaccines and providing durable protection in animal models.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on the development of innovative therapeutics, including vaccines for infectious diseases like mpox and smallpox.
YTD Price Performance: -60.52%
Average Trading Volume: 1,975,170
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $72.79M
See more data about TNXP stock on TipRanks’ Stock Analysis page.